The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2015;8(4): 4‑10

DOI: 10.17116/dokkardio201544-10

Read: 2431 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2015;8(4):4‑10. (In Russ.)
https://doi.org/10.17116/dokkardio201544-10

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217—223.
  2. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation 2014; 129(3):e28—292.
  3. Franklin S.S. Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist’s point of view. Pathol Biol (Paris) 1999;47:594—603.
  4. Franklin S.S., Jacobs M.J., Wong N.D., et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001;37:869—874.
  5. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560—2572.
  6. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827—838.
  7. Hsu C.Y., McCulloch C.E., Darbinian J., et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923—928.
  8. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557—1562.
  9. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765—774.
  10. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903—1913.
  11. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757—764.
  12. Vasan R.S., Larson M.G., Leip E.P., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291—1297.
  13. Sundström J., Arima H., Jackson R., et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184—191.
  14. Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224—2260.
  15. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955—1964.
  16. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents: asystematic review and meta-analysis. JAMA 1997;277:739—745.
  17. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with iso- lated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255—3264.
  18. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887—1898.
  19. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115—2127.
  20. Ogihara T., Saruta T., Rakugi H., et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension study. Hypertension 2010;56:196—202.
  21. Verdecchia P., Staessen J.A., Angeli F., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525—533.
  22. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575—1585.
  23. Benavente O.R., Coffey C.S., Conwit R., et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 ran- domised trial. Lancet 2013;382:507—515.
  24. Working group report: Expert Panel on a Hypertension Treatment Trial Initiative meeting summary, 2007. Bethesda, MD, National Heart Lung and Blood Institute (http://www.nhlbi.nih.gov/sites/www .nhlbi.nih.gov/files/hypertsnsion-full.pdf).
  25. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545—1553.
  26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hy- pertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981—2997.
  27. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352—358.
  28. Ambrosius W.T., Sink K.M., Foy C.G., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532—546.
  29. Office for Human Research Protections. OHRP guidance on unanticipated problems and adverse events. 2007 (http:// www.hhs.gov/ohrp/policy/advevntguid.html).
  30. Food and Drug Administration. Code of Federal Regulations. Title 21CFR312.32a, 2013 (http://www.access- data.fda.gov/scripts/cdrh/cfdocs/cfcfr/ cfrsearch.cfm?fr=312.32).
  31. Bakris G.L., Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685—693.
  32. Apperloo A.J, de Zeeuw D., de Jong P.E. A short-term antihypertensive treatment- induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793—797.
  33. Liu L., Zhang Y., Liu G., et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23:2157—2172.
  34. Margolis K.L., O’Connor P.J., Morgan T.M., et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014;37:1721—1728.
  35. Nwankwo T., Yoon S.S., Burt V., Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief 2013;133:1—8.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.